Quarterly report pursuant to Section 13 or 15(d)

Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)

v3.23.3
Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 18, 2023
USD ($)
position
shares
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jan. 01, 2025
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Gain on sale of Pelican   $ (2,121) $ 0 $ (2,121) $ 0  
Net loss from discontinued operations   0 $ 9,241 1,665 $ 25,191  
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc.            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Consideration paid for an interest in potential development milestone $ 15,000          
Goodwill written off   4,100   4,100    
Gain on sale of Pelican   (2,100)   $ (2,100)    
Business exit costs $ 1,200          
Net loss from discontinued operations   $ 70        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Common Stock            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Shares received as consideration | shares 2,146,957          
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Preferred Stock            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Shares received as consideration | shares 4,278,293          
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Restricted Stock Awards            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Shares received as consideration | shares 474,746          
Primrose Bio            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Consideration paid for an interest in potential development milestone $ 15,000          
Interest in potential development milestone (as a percent) 50.00%          
Forecast | Primrose Bio | PeliCRM197            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Sales revenue milestone           $ 3,000
Forecast | Primrose Bio | PeliCRM197 | Below 3 million            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Interest in sales revenue (as a percent)           25.00%
Forecast | Primrose Bio | PeliCRM197 | Above 3 million            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Interest in sales revenue (as a percent)           35.00%
Primordial Genetics            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations            
Number of contracts | position 2